BRIAN FINLEY: Open Payments
NPI 1144278482 · BELLEVUE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,216 in 129 payments from 26 companies in 2025. Trend: 2023 $3,111 · 2024 $3,608 · 2025 $3,216
Food & beverage: $3,216
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $759 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $486 |
| AstraZeneca Pharmaceuticals LP | 9 | $288 |
| Vanda Pharmaceuticals Inc. | 6 | $215 |
| Lundbeck LLC | 9 | $208 |
| E.R. Squibb & Sons, L.L.C. | 5 | $203 |
| Otsuka America Pharmaceutical, Inc. | 11 | $138 |
| Supernus Pharmaceuticals, Inc. | 2 | $137 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Lilly USA, LLC | 7 | $110 |
Products named: CAPLYTA, VRAYLAR, REXULTI, QULIPTA, COBENFY, FANAPT, BREZTRI, Qelbree.
Industry payments across NE — which companies pay providers there.
